Yoshiaki Uyama

Pharmaceuticals and Medical Devices Agency

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (5)

Kazuhiro Kajiyama

Pharmaceuticals and Medical Devices Agency

JAPAN

View details

Yusuke Okada

Keio University

JAPAN

View details

Yasuhiro Fujiwara

Chief Executive

Pharmaceuticals and Medical Devices Agency

JAPAN

View details

Daisuke Tanaka

Osaka University

JAPAN

View details

Yuki Kinoshita

Pharmaceuticals and Medical Devices Agency

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yoshiaki Uyama

Research Interests

Explore related searches

Contact this professor

Articles (10)

Expediting Drug Development in Japan: A PMDA Perspective

Japan's Perspective on Facilitating Drug Development Through Asian Cooperation in Multi‐Regional Clinical Trials: Insights From Regulatory Research

Characteristics of Multi-Regional Clinical Trials Conducted in Asia, Focusing on Japan’s Participation and Small/Medium Companies-Sponsored Trials

Risk of Thrombocytopenia by <scp>SSRIs</scp> or <scp>SNRIs</scp> in Patients With Depression Based on <scp>MID</scp>‐<scp>NET</scp>: A Cohort Study in Japan

New Function for Safety Signal Monitoring in MID‐NET®: The Case of an Anti‐COVID‐19 Drug

PMDA Perspective on Use of Real‐World Data and Real‐World Evidence as an External Control: Recent Examples and Considerations

Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET ® in Japan

PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage

Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based Companies

Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan

Collaborators (5)

Kazuhiro Kajiyama

Yusuke Okada

Yasuhiro Fujiwara

Daisuke Tanaka

Yuki Kinoshita

Make your next move.